Inspira Technologies received a notification from Nasdaq about non-compliance with the minimum bid price requirement. The company’s shares must be at least $1.00 for 10 consecutive days by August 10, 2026, to regain compliance. If not, a second compliance period may be granted. Failure to comply could result in delisting. Inspira intends to monitor share prices and explore options to meet requirements. The company focuses on respiratory support and blood monitoring solutions, with FDA-cleared products like INSPIRA ART100. Forward-looking statements caution risks and uncertainties. For more information, visit Inspira Technologies’ website.

Read more at GlobeNewswire: Inspira Technologies Announces Receipt of Nasdaq